cagrilintide clinical trials results Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Cagrilintide vs Tirzepatide Compared -

Triple agonists with GLP1, GIP and glucagon Given the efficacy and benefits of the dual GLP-1/GIP RA tirzepatide and the dual GLP-1/glucagon RA, a triple agonist targeting all three receptors (GLP-1/GIP/glucagon) may result in superior WL and glycaemic control than dual agonists

Tip it is easier if you have a syringe that holds a greater amount than you are injecting

Proper storage, labeling, and restricted access are essential to prevent misuse or unintended exposure

Researchers with a history of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome should avoid both compounds due to the GLP-1 receptor activation component

S., Glozman, O